## Franco Rabbia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5549190/publications.pdf

Version: 2024-02-01

82 3,766 28 60
papers citations h-index g-index

82 82 82 3802 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Comparison of nurse attended and unattended automated office blood pressure with conventional measurement techniques in clinical practice. Journal of Human Hypertension, 2022, 36, 833-838.	2.2	5
2	Knowledge on arterial hypertension in general population: Results from a community pharmacy screening program. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1081-1086.	2.6	1
3	Assessment of Anti-Hypertensive Drug Adherence by Serial Aldosterone-To-Renin Ratio Measurement. Frontiers in Pharmacology, 2021, 12, 668843.	3.5	O
4	Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3655-e3664.	3.6	16
5	A structured physical activity program in an adolescent population with overweight and obesity: a prospective interventional study. Applied Physiology, Nutrition and Metabolism, 2021, , .	1.9	4
6	A Non-Invasive Method for Detection of Antihypertensive Drugs in Biological Fluids: The Salivary Therapeutic Drug Monitoring. Frontiers in Pharmacology, 2021, 12, 755184.	<b>3.</b> 5	5
7	Prevalence of Hypokalemia and Primary Aldosteronism in 5100 Patients Referred to a Tertiary Hypertension Unit. Hypertension, 2020, 75, 1025-1033.	2.7	60
8	Pregnancy-Related Complications in Patients With Fibromuscular Dysplasia. Hypertension, 2020, 76, 545-553.	2.7	10
9	Predictors of blood pressure control in patients with resistant hypertension after intensive management in two expert centres: the Brussels-Torino experience. Blood Pressure, 2019, 28, 336-344.	1.5	9
10	Assessment of a non-physician screening program for hypertension and cardiovascular risk in community pharmacies. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 1316-1322.	2.6	8
11	Prevalence and characteristics of renal artery fibromuscular dysplasia in hypertensive women below 50 years old. European Journal of Clinical Investigation, 2019, 49, e13166.	3.4	7
12	Trisomy of the Short Arm of Chromosome 12 Associated with High Cardiovascular Risk: A Case Report. High Blood Pressure and Cardiovascular Prevention, 2019, 26, 143-144.	2.2	1
13	Comparison of Automated Office Blood Pressure With Office and Out-Off-Office Measurement Techniques. Hypertension, 2019, 73, 481-490.	2.7	57
14	A simple UHPLC-PDA method with a fast dilute-and-shot sample preparation for the quantification of canrenone and its prodrug spironolactone in human urine samples. Journal of Pharmacological and Toxicological Methods, 2018, 94, 29-35.	0.7	6
15	Effectiveness of Renal Denervation in Resistant Hypertension: A Meta-Analysis of 11 Controlled Studies. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 167-176.	2.2	20
16	Therapeutic drug monitoringâ€guided definition of adherence profiles in resistant hypertension and identification of predictors of poor adherence. British Journal of Clinical Pharmacology, 2018, 84, 2535-2543.	2.4	34
17	Impact of psychological profile on drug adherence and drug resistance in patients with apparently treatment-resistant hypertension. Blood Pressure, 2018, 27, 358-367.	1.5	20
18	UHPLC–MS/MS method with sample dilution to test therapeutic adherence through quantification of ten antihypertensive drugs in urine samples. Journal of Pharmaceutical and Biomedical Analysis, 2017, 142, 279-285.	2.8	33

#	Article	IF	CITATIONS
19	Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in PrimaryÂCareÂPractice. Journal of the American College of Cardiology, 2017, 69, 1811-1820.	2.8	520
20	Procedural Reassessment of Radiofrequency Renal Denervation in Resistant Hypertensive Patients. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 187-192.	2.2	0
21	Diagnostic accuracy of aldosterone and renin measurement by chemiluminescent immunoassay and radioimmunoassay in primary aldosteronism. Journal of Hypertension, 2016, 34, 920-927.	0.5	61
22	Evaluation of a short home blood pressure measurement in an outpatient population of hypertensives. Clinical and Experimental Hypertension, 2016, 38, 673-679.	1.3	5
23	Adherence to antihypertensive therapy and therapeutic dosage of antihypertensive drugs. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 341-345.	2.2	13
24	UHPLCâ€"MS/MS method with protein precipitation extraction for the simultaneous quantification of ten antihypertensive drugs in human plasma from resistant hypertensive patients. Journal of Pharmaceutical and Biomedical Analysis, 2016, 129, 535-541.	2.8	39
25	Aortic root dilatation in the children and young adults: prevalence, determinants, and association with target organ damage. Journal of the American Society of Hypertension, 2016, 10, 782-789.	2.3	10
26	Evaluation of Adherence Should Become an Integral Part of Assessment of Patients With Apparently Treatment-Resistant Hypertension. Hypertension, 2016, 68, 297-306.	2.7	147
27	Antihypertensive Bridge Therapy by Continuous Drug Infusion With an Elastomeric Pump in Device-Resistant Hypertension. Hypertension, 2016, 67, e3-4.	2.7	1
28	Prevalence of erectile dysfunction in a cohort of Italian hypertensive subjects. Clinical and Experimental Hypertension, 2016, 38, 143-149.	1.3	5
29	Physical and Chemical Stability of Urapidil in 0.9% Sodium Chloride in Elastomeric Infusion Pump. International Journal of Pharmaceutical Compounding, 2016, 20, 343-346.	0.0	0
30	Ambulatory Blood Pressure Monitoring–Derived Shortâ€√erm Blood Pressure Variability in Primary Aldosteronism. Journal of Clinical Hypertension, 2015, 17, 603-608.	2.0	10
31	Echocardiographic aortic root dilatation in hypertensive patients. Journal of Hypertension, 2014, 32, 1928-1935.	0.5	57
32	Renal Sympathetic Denervation in a Previously Stented Renal Artery. Journal of Clinical Hypertension, 2014, 16, 238-239.	2.0	3
33	Effectiveness of Blood Pressure Educational and Evaluation Program for the Improvement of Measurement Accuracy Among Nurses. High Blood Pressure and Cardiovascular Prevention, 2013, 20, 77-80.	2.2	25
34	Long-Term Cardio- and Cerebrovascular Events in Patients With Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4826-4833.	3.6	348
35	Comparison among Different Screening Tests for Diagnosis of Adolescent Hypertension. ISRN Hypertension, 2013, 2013, 1-3.	0.2	5
36	Echocardiographic Abnormalities in the Assessment of Cardiac Organ Damage in Never-Treated Hypertensive Patients. Clinical and Experimental Hypertension, 2012, 34, 463-469.	1.3	2

#	Article	IF	Citations
37	Silent Cerebrovascular Damage and Its Early Correlates in Essential Hypertensive Patients. Clinical and Experimental Hypertension, 2012, 34, 510-516.	1.3	O
38	18-Hydroxycorticosterone, 18-Hydroxycortisol, and 18-Oxocortisol in the Diagnosis of Primary Aldosteronism and Its Subtypes. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 881-889.	3.6	105
39	Left atrial enlargement in essential hypertension: Role in the assessment of subclinical hypertensive heart disease. Blood Pressure, 2012, 21, 88-96.	1.5	22
40	Appropriateness of Referral to a European Society of Hypertension Center of Excellence. Journal of Clinical Hypertension, 2012, 14, 729-730.	2.0	2
41	Aortic size index enlargement is associated with central hemodynamics in essential hypertension. Hypertension Research, 2011, 34, 126-132.	2.7	23
42	Ventricular repolarization before and after treatment in patients with secondary hypertension due to renal-artery stenosis and primary aldosteronism. Hypertension Research, 2011, 34, 1078-1081.	2.7	4
43	Prevalence and Characteristics of Familial Hyperaldosteronism. Hypertension, 2011, 58, 797-803.	2.7	128
44	Efficacy of antihypertensive treatment based on plasma renin activity: An open label observational study. Blood Pressure, 2010, 19, 218-224.	1.5	4
45	Effects of Antihypertensive Drugs on the Renin-Angiotensin System in Essential Hypertension. High Blood Pressure and Cardiovascular Prevention, 2010, 17, 109-115.	2.2	1
46	Hypertension and cerebrovascular damage. Atherosclerosis, 2009, 205, 331-341.	0.8	77
47	Prognostic Relevance of Masked Hypertension in Subjects With Prehypertension. American Journal of Hypertension, 2008, 21, 879-883.	2.0	43
48	Is Renin-Based Treatment a Reasonable Strategy to Treat Essential Hypertension?. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 121-125.	2.2	2
49	Hypertension and Cognitive Function. Clinical and Experimental Hypertension, 2008, 30, 701-710.	1.3	58
50	Roles of Clinical Criteria, Computed Tomography Scan, and Adrenal Vein Sampling in Differential Diagnosis of Primary Aldosteronism Subtypes. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1366-1371.	3.6	149
51	Prolonged QT Interval and Reduced Heart Rate Variability in Patients with Uncomplicated Essential Hypertension. Hypertension Research, 2008, 31, 2003-2010.	2.7	31
52	Antihypertensive Drugs and the Sympathetic Nervous System. Journal of Cardiovascular Pharmacology, 2007, 50, 487-496.	1.9	40
53	Baroreflex sensitivity correlates with left ventricular morphology and diastolic function in essential hypertension. Journal of Hypertension, 2007, 25, 1655-1664.	0.5	31
54	Effects of birth weight on spontaneous baroreflex sensitivity in adult life. Nutrition, Metabolism and Cardiovascular Diseases, 2007, 17, 303-310.	2.6	9

#	Article	IF	Citations
55	QT interval in patients with primary aldosteronism and low-renin essential hypertension. Journal of Hypertension, 2006, 24, 2459-2464.	0.5	25
56	Prevalence and Characteristics of the Metabolic Syndrome in Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 454-459.	3.6	340
57	Comparison between generalized retinal arteriolar narrowing and left ventricular mass in young untreated hypertensive patients. Blood Pressure, 2006, 15, 308-312.	1.5	7
58	Bradykinin B2 receptor gene (???58T/C) polymorphism influences baroreflex sensitivity in never-treated hypertensive patients. Journal of Hypertension, 2005, 23, 63-69.	0.5	27
59	Diagnosis of Surgically-Treatable Forms of Primary Aldosteronism. Current Hypertension Reviews, 2005, 1, 259-265.	0.9	8
60	Hypertension in Obstructive Sleep Apnoea. Vascular Disease Prevention, 2005, 2, 29-35.	0.2	2
61	Weekly Gemcitabine plus Fluorouracil-Folinic Acid Given Weekly for Two Days in Patients with???Advanced Pancreatic Cancer. Clinical Drug Investigation, 2004, 24, 661-670.	2.2	7
62	Heart Rate Variability and Baroreflex Sensitivity during Fosinopril, Irbesartan and Atenolol Therapy in Hypertension. Clinical Drug Investigation, 2004, 24, 651-659.	2.2	8
63	Assessment of Cardiac Autonomic Modulation during Adolescent Obesity. Obesity, 2003, 11, 541-548.	4.0	148
64	Drug Effects on Aldosterone/Plasma Renin Activity Ratio in Primary Aldosteronism. Hypertension, 2002, 40, 897-902.	2.7	346
65	Blood Pressure in Patients with Primary Aldosteronism Is Influenced by Bradykinin B <sub>2</sub> Receptor and α-Adducin Gene Polymorphisms. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3337-3343.	3.6	30
66	Protective effect of anti-hypertensive treatment on cognitive function in essential hypertension. Journal of the Neurological Sciences, 2002, 203-204, 147-151.	0.6	77
67	Circadian Blood Pressure Patterns and Life Stress. Psychotherapy and Psychosomatics, 2002, 71, 350-356.	8.8	24
68	Heart rate variability pattern in adolescent obesity. American Journal of Hypertension, 2002, 15, A196.	2.0	0
69	HEART RATE VARIABILITY AND LEFT VENTRICULAR DIASTOLIC FUNCTION IN PATIENTS WITH BORDERLINE HYPERTENSION WITH AND WITHOUT LEFT VENTRICULAR HYPERTROPHY. Clinical and Experimental Hypertension, 2001, 23, 77-87.	1.3	19
70	α1-Adrenergic receptor subtypes in peripheral blood lymphocytes of essential hypertensives. Journal of Hypertension, 2001, 19, 1847-1854.	0.5	10
71	Angiotensin-converting enzyme and angiotensinogen gene polymorphisms are non-randomly distributed in oral contraceptive-induced hypertension Journal of Hypertension, 2001, 19, 713-719.	0.5	8
72	Heart rate variability in childhood obesity. Clinical Autonomic Research, 2001, 11, 87-91.	2.5	99

#	Article	IF	CITATIONS
73	Paraneoplastic Hyperaldosteronism Associated with Non-Hodgkin's Lymphoma. New England Journal of Medicine, 2001, 344, 1558-1559.	27.0	7
74	CYP11B2Gene Polymorphisms in Idiopathic Hyperaldosteronism. Hypertension, 2000, 35, 694-698.	2.7	72
75	Assessment of Heart Rate Variability after Calcium Antagonist and ??-Blocker Therapy in Patients with Essential Hypertension. Clinical Drug Investigation, 1999, 17, 111-118.	2.2	5
76	Relationship between Birth Weight and Blood Pressure in Adolescence. Preventive Medicine, 1999, 29, 455-459.	3.4	17
77	Diagnosis of Glucocorticoid-Remediable Aldosteronism in Primary Aldosteronism: Aldosterone Response to Dexamethasone and Long Polymerase Chain Reaction for Chimeric Gene. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2573-2575.	3.6	121
78	Noninvasive assessment of spontaneous baroreflex sensitivity in patients with liver cirrhosis. Liver, 1998, 18, 420-426.	0.1	15
79	Comparison of the Effect of Carvedilol and Atenolol on Circadian Blood Pressure Profile in Patients with Essential Hypertension. Clinical Drug Investigation, 1997, 14, 369-375.	2.2	0
80	Plasma Immunoreactive Endothelin-1 in Primary Hyperaldosteronism. American Journal of Hypertension, 1994, 7, 559-561.	2.0	11
81	Twenty-Four-Hour Power Spectral Analysis by Maximum Entropy Method of Blood Pressure in Primary Hyperaldosteronism. Blood Pressure, 1993, 2, 189-196.	1.5	12
82	Plasma endothelin levels in cirrhotic subjects. Journal of Hepatology, 1992, 15, 85-87.	3.7	45